News Sentiment

CAPR sentiment intelligence

Capricor Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.44 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-9.6% over one week, -31.5% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Negative

Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -9.6% Price reacting lower
Trend fit Trend inactive -31.5% over four weeks
Fair value 59.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 36
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 8
Stocktwits 7
Stock Titan 6
Simply Wall Street 3
Moomoo 3
Sahm 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 15
Regulatory and legal 8
Analyst action 5
Guidance 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Stock Titan Direct company coverage

Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan

Capricor Therapeutics EVP and General Counsel Karen Krasney exercised stock options for 24,100 shares at $3.18 per share and subsequently sold all 24,100 shares in open-market transactions at a weighted average price of $30.38 per share. These sales were executed under a pre-arra

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 01:39
Source
Stock Titan